US infant formula firm Abbott Laboratories has reported flat half-year sales from its nutrition division, which houses its baby and adult nutrition businesses.
Abbott said its sales, excluding the impact of foreign currency, inched up 0.7% in the first six months of the year. On a reported basis, including foreign exchange, sales were down 1.2% at US$3.36bn.
Go deeper with GlobalData
The company said its pediatric nutrition sales increased 1.1% in the second quarter when currency fluctuations were excluded from the results and fell 0.5% with the foreign exchange impact included.
Abbott said the disruption to its sales last August after supplier Fonterra recalled a batch of whey protein concentrate amid a botulism scare impacted the year-over-year sales comparison in its international pediatric nutrition business by $40m.
Abbott said it is “recapturing share” in the affected markets. It launched several products during the quarter and opened a new nutrition manufacturing plant in China, which will manufacture its Similac Qinti infant formula.
Worldwide adult nutrition sales increased 5.7% during the second quarter when the impact of foreign exchange was removed from the results. Including currency fluctuations, sales were up 4.4%.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
